Demographic characteristics of the study population
| Complete responders | Partial responders | Non-responders | |
| Patients, n (%) | 32 (29) | 37 (34) | 41 (37) |
| Age (years) | 32 (28–35) | 35 (29–38) | 31 (29–34) |
| Sex (female/male) | 31/1 | 35/2 | 38/3 |
| Immunosuppressive agents (n) | |||
| Cyclophosphamide | 6 | 8 | 11 |
| Mycophenolate mofetil | 18 | 11 | 14 |
| Mycophenolate sodium | 1 | 12 | 8 |
| Tacrolimus | 6 | 6 | 7 |
| Azathioprine | 1 | 0 | 1 |
| International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 classification (n=76) | |||
| III or III+V | 4 | 1 | 5 |
| IV or IV+V | 15 | 20 | 19 |
| V | 3 | 4 | 5 |
| Activity index (n=40) | 6.3 (3.6–9.1) | 10.4 (6.8–14.1) | 10.6 (3.6–9.1) |
| Chronicity index (n=40) | 1.9 (0.8–3.0) | 2.2 (0.7–3.7) | 3.4 (2.3–4.5) |
| Urinary protein to creatinine ratio (g/g) | 3.3 (2.5–4.2) | 6.2 (4.8–7.7) | 5.5 (3.8–7.2) |
| Serum creatine (mg/dL) | 0.9 (0.78–0.99) | 1.0 (0.84–1.08) | 0.9 (0.78–0.99) |
| C3 (mg/dL) | 83 (41–448) | 95 (35–773) | 83 (50–112) |
| Anti-dsDNA (IU) | 335 (151–518) | 461 (255–668) | 484 (0–1013 |
| Serum albumin (g/dL) | 2.8 (2.5–3.2) | 2.9 (2.6–3.2) | 2.7 (2.4–3.0) |
| uTWEAK (pg/mgCr) | 0.58 (0.36–0.81) | 2.18 (0.78–3.58) | 1.11 (0.65–1.58) |
Continuous variables presented as the mean (95% CI).
uTWEAK, urine TWEAK.